FOR IMMEDIATE RELEASE
Contact: TEVA Pharmaceuticals USA Selects In.vision
Xpress Author for Production of Structured Product Labels (SPL) Under the
Physician’s Labeling Rule (PLR) About Teva Pharmaceuticals About
In.vision
Founded in 1996,
In.vision Research Corporation is the leading provider of software for
Enterprise XML Authoring. In.vision's Xpress Author products enable
Microsoft Word users to easily and transparently produce XML content, making
In.vision the clear choice for today's business authors. In.vision customers
create content that is critical to national security, prescription drug
safety, publishing processes, financial services, and enterprise content
management. With corporate offices in both the U.S. and Europe, In.vision
delivers and supports its products through a global network of industry
focused business partners. For more information on In.vision, please visit
www.invisionresearch.com
David Dalton
Business Development Manager
In.vision research Corp.
ddalton@invisionresearch.com
(727) 822-7200
Saint Petersburg, Florida March 14, 2007.
In.vision Research Corporation, the leading provider of software for enterprise
XML authoring, announced today that TEVA Pharmaceuticals USA has joined the
growing list of companies that have selected Xpress Author for Microsoft Word to
prepare Structured Product Labels (SPL) according to the Physicians Labeling
Rule.
According to the Food and Drug Administration (FDA), the Physician’s Labeling
Rule is part of a larger FDA initiative to manage the risks of medical product
use and reduce medical errors by healthcare professions, as well as enable them
to better communicate risk information to their patients . Developments in
recent years have contributed to an increase in the length, detail, and
complexity of prescribing information for drugs. The revisions will make it
easier for healthcare professionals to access, read, and use prescribing
information, thereby increasing the extent to which they rely on it to obtain
information on prescribing, dispensing, and administering prescription drugs.
These revisions should enhance the safe and effective use of prescription drug
products and in turn reduce the number of adverse reactions resulting from
medication errors due to misunderstood or incorrectly applied drug information.
“TEVA USA is a worldwide leader in generic pharmaceuticals and according to the
company, has one of the best overall FDA approval records in the industry for
their drug submissions,” explained John Friske, In.vision CEO. “We are pleased
to play a role by supporting TEVA in the preparation of these submissions
according to the new Physician’s Labeling Rule without them needing to train
their authors in XML and other complex computer technologies.”
Teva Pharmaceuticals USA is the leading generic pharmaceutical company,
marketing products from a wide range of therapeutic areas including analgesic,
anti-infective, cardiovascular, oncology, CNS, dermatological and
anti-inflammatory. Dosage forms include extended and immediate release tablets
and capsules, injectables, creams, ointments, solutions, and suspensions. Teva
USA products are marketed to chains, wholesalers, distributors, hospitals,
managed care entities, and government agencies. To learn more, visit
www.tevausa.com